Cargando…
Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: A study from the RelevarEM registry
We aimed to evaluate mortality and causes of death among Argentinean neuromyelitis optica spectrum disorder (NMOSD) patients and identify predictors of death. Retrospective study included 158 NMOSD patients and 11 (7%) patients died after 11 years of follow-up for a total exposure time of 53,345 day...
Autores principales: | Carnero Contentti, Edgar, Lopez, Pablo A, Pettinicchi, Juan Pablo, Criniti, Juan, Pappolla, Agustín, Miguez, Jimena, Cristiano, Edgardo, Patrucco, Liliana, Liwacki, Susana, Tkachuk, Verónica, Balbuena, María E, Vrech, Carlos, Deri, Norma, Correale, Jorge, Marrodan, Mariano, Ysrraelit, María C, Leguizamon, Felisa, Luetic, Geraldine, Menichini, María L, Tavolini, Darío, Mainella, Carolina, Zanga, Gisela, Burgos, Marcos, Hryb, Javier, Barboza, Andrés, Lazaro, Luciana, Alonso, Ricardo, Fernández Liguori, Nora, Nadur, Débora, Alonso Serena, Marina, Caride, Alejandro, Paul, Friedemann, Rojas, Juan I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580714/ https://www.ncbi.nlm.nih.gov/pubmed/37854639 http://dx.doi.org/10.1177/20552173231205444 |
Ejemplares similares
-
Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM
por: Rojas, Juan I., et al.
Publicado: (2022) -
Assessing attacks and treatment response rates among adult patients
with NMOSD and MOGAD: Data from a nationwide registry in
Argentina
por: Contentti, Edgar Carnero, et al.
Publicado: (2021) -
Achieving no evidence of disease activity-3 in highly active multiple
sclerosis patients treated with cladribine and monoclonal
antibodies
por: Alonso, Ricardo, et al.
Publicado: (2023) -
Family planning in Argentinian women with multiple sclerosis: An important yet seldom approached issue
por: Alonso, Ricardo, et al.
Publicado: (2021) -
Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
por: ROJAS, Juan Ignacio, et al.
Publicado: (2021)